Altimmune, Inc. (NASDAQ:ALT) Stock Holdings Trimmed by Wealth Effects LLC

Wealth Effects LLC lessened its position in shares of Altimmune, Inc. (NASDAQ:ALT) by 6.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,850 shares of the company’s stock after selling 2,200 shares during the period. Wealth Effects LLC’s holdings in Altimmune were worth $237,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ALT. Larson Financial Group LLC bought a new position in Altimmune during the 3rd quarter worth $31,000. 180 Wealth Advisors LLC bought a new position in shares of Altimmune during the fourth quarter worth about $78,000. XTX Topco Ltd acquired a new stake in shares of Altimmune in the 2nd quarter worth about $96,000. PFG Investments LLC acquired a new stake in shares of Altimmune in the 4th quarter worth about $96,000. Finally, Stifel Financial Corp lifted its position in Altimmune by 77.4% in the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after purchasing an additional 7,746 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Analyst Upgrades and Downgrades

ALT has been the subject of several analyst reports. UBS Group assumed coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Stifel Nicolaus started coverage on Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $20.83.

Altimmune Stock Down 1.0 %

Shares of ALT opened at $6.93 on Wednesday. The firm has a market cap of $492.86 million, a price-to-earnings ratio of -4.47 and a beta of 0.22. The company’s fifty day moving average is $7.87 and its 200-day moving average is $7.19. Altimmune, Inc. has a 12 month low of $5.28 and a 12 month high of $14.84.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter. During the same period in the previous year, the company earned ($0.39) EPS. As a group, research analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.